文献速递慢阻肺哮喘

生命历程FEV1/FVC轨迹与中年呼吸道症状的关联:两项前瞻性队列研究分析

Associations between life-course FEV1/FVC trajectories and respiratory symptoms up to middle age: analysis of data from two prospective cohort studies.
PubMed 文献 · Lancet Respir Med · 2024-11-29

基于塔斯马尼亚纵向健康研究(TAHS,n=2421)和CARDIA队列(n=3153),分析生命历程中FEV1/FVC轨迹与中年呼吸道症状的关联。最受损轨迹与 predominant wheeze 及几乎所有呼吸道症状显著相关,且在无COPD的个体中仍持续存在。

要点

  • 受损FEV1/FVC轨迹者中年期呼吸道症状负担增加,以喘息为主。
  • 即使未达COPD spirometric标准,症状关联仍存在。
  • 快速下降轨迹者早年即可出现喘息和咳痰/支气管炎。

核心结论

  • 在两项独立队列中,受损FEV1/FVC轨迹者常有长期喘息和咳痰/支气管炎病史。
  • 在47-64岁未进展为COPD的个体中,喘息是主要症状。

研究设计与样本

  • 分析两项人群为基础的前瞻性队列:TAHS(澳大利亚,6-7岁入组,随访至平均53岁,范围51-55岁)和CARDIA(美国,平均25岁入组,范围18-30岁,随访至平均55岁,范围47-64岁)。
  • 采用潜在类别分析衍生症状谱,组基建模衍生支气管舒张前FEV1/FVC轨迹。
  • TAHS症状谱分析n=2421,CARDIA n=3153。

主要发现

  • 在三个最受损轨迹中,与 predominant wheeze 的关联随FEV1/FVC受损加重而增加,且在无spirometry定义COPD者中持续存在。
  • 快速下降轨迹者中,TAHS年龄<14岁者265人中54人(20%)报告喘息和习惯性咳痰或支气管炎;CARDIA年龄≤30岁者123人中31人(25%)报告两者。

临床怎么用

  • 对FEV1/FVC轨迹受损者应关注呼吸道症状负担,即使未达COPD标准。
  • 早期识别快速下降轨迹可能有助于干预喘息和咳痰症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Life-course lung function trajectories leading to airflow obstruction, as measured by impaired FEV1/FVC (forced vital capacity), precede the onset of chronic obstructive pulmonary disease (COPD). We aimed to investigate whether individuals on impaired FEV1/FVC trajectories have an increased burden of respiratory symptoms, including those who do not meet the spirometric criteria for COPD. METHODS: We analysed serial life-course data from two population-based cohort studies separately, which included respiratory symptoms and spirometry: the Tasmanian Longitudinal Health Study (TAHS, Australia) cohort was recruited at age 6-7 years and followed up until middle age (mean age 53 years; range 51-55); and the Coronary Artery Risk Development in Young Adults (CARDIA, USA) cohort was recruited at a mean age of 25 years (range 18-30) and followed up to a mean age of 55 years (range 47-64). Participants' symptom profiles at ages 53 and 55 years were derived by latent class analysis. Symptom profiles were compared across pre-bronchodilator FEV1/FVC trajectories derived by group-based modelling, then restricted to those without COPD defined by post-bronchodilator airflow obstruction (FEV1/FVC <5th percentile) at ages 51-55 years and 47-64 years. FINDINGS: Six FEV1/FVC trajectories previously derived for TAHS were replicated in CARDIA. Optimal models identified five symptom profiles in TAHS (n=2421) and six in CARDIA (n=3153). For both cohorts, the most impaired FEV1/FVC trajectory (early low, rapid decline in TAHS; low peak, rapid decline in CARDIA) was associated with predominant wheeze (multinomial odds ratio [mOR] 6·71 [95% CI 4·10-10·90] in TAHS and 9·90 [4·52-21·70] in CARDIA) and nearly all respiratory symptoms (4·95 [2·52-9·74] and 14·80 [5·97-36·60]) at age 51-55 years in TAHS and age 47-64 years in CARDIA, compared with the average trajectory. Among individuals belonging to the three most impaired trajectories, the associations with predominant wheeze increased with worsening FEV1/FVC impairment and persisted when considering only those without spirometry-defined COPD. Additionally, for those belonging to the two rapid decline trajectories, both wheezing and usual phlegm or bronchitis were reported by 54 (20%) of 265 participants younger than 14 years in TAHS and by 31 (25%) of 123 participants aged 30 years or younger in CARDIA. INTERPRETATION: In two independent cohorts that collected similar data, people on impaired FEV1/FVC trajectories often had a longstanding history of both wheeze and phlegm or bronchitis, and wheeze was the predominant symptom in individuals aged 47-64 years among those who had not already progressed to COPD. FUNDING: National Health and Medical Research Council (Australia); The University of Melbourne; Clifford Craig Medical Research Trust; Victorian, Queensland & Tasmanian Asthma Foundations; Royal Hobart Hospital Research Foundation; Helen MacPherson Smith Trust; GlaxoSmithKline; National Heart, Lung, and Blood Institute of the US National Institutes of Health.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Perret JL, Bui DS, Pistenmaa C, et al. Associations between life-course FEV1/FVC trajectories and respiratory symptoms up to middle age: analysis of data from two prospective cohort studies. Lancet Respir Med. 2024. PMID: 39615504. doi:10.1016/S2213-2600(24)00265-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。